Market cap
$125 Mln
Revenue (TTM)
$302 Mln
P/E Ratio
--
P/B Ratio
8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -13.36 | -35.59 | -3.75 | 15.26 | 7.90 |
| EBIT | -696.52 | -243.86 | -91.72 | -38.35 | -29.15 |
| Net Profit | -1,611.17 | -305.26 | -121.86 | -192.07 | -172.60 |
| EPS | -622.72 | -294.40 | -104.51 | -151.71 | -165.69 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Jun-24 | Jun-23 | Jun-22 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -- | -- | 253.87 | -13.10 | -12.61 |
| Return on Capital
| -- | -- | 253.87 | -12.09 | -10.61 |
| Return on Assets
| -- | -- | -94.49 | -9.29 | -8.49 |
| Debt to Equity (x)
| -- | -- | -- | -- | -- |
Profitability
ROCE
253.87
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
253.87
|
-12.09
|
10.71
|
-10.61
|
20.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
253.87
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
253.87
|
-13.10
|
12.19
|
-12.61
|
24.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-94.49
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
-94.49
|
-9.29
|
9.30
|
-8.49
|
16.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
16.67
|
--
|
29.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-291,875.00
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
-291,875.00
|
-600.62
|
12.71
|
-217.07
|
22.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-1.00
--
Year on year growth in net sales
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
-1.00
|
-0.60
|
0.05
|
-0.58
|
0.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
-39.88
|
--
|
49.10
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-91.75
--
Year on year growth in profit after tax
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
-91.75
|
-10.43
|
-40.54
|
-191.30
|
54.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-0.92
--
Year on year growth in earnings per share
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
-0.92
|
-0.10
|
-0.41
|
-1.91
|
0.51
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
0.08
|
--
|
0.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
0.00
|
--
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.33
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
0.33
|
0.55
|
3.63
|
0.93
|
4.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
0.30
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
0.30
|
0.44
|
2.46
|
0.85
|
2.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
46.68
|
--
|
49.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
40.67
|
14.18
|
38.05
|
16.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
--
Sales / Average Total Assets
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
0.00
|
0.02
|
0.73
|
0.04
|
0.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
18,821.79
--
Average Debtors / Sales * 365
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
18,821.79
|
2,201.59
|
55.28
|
1,032.37
|
52.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
-25,438.99
--
Average Inventory / Sales * 365
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
-25,438.99
|
1,568.12
|
182.62
|
1,264.55
|
216.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
-126,471.19
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
-126,471.19
|
571.47
|
37.19
|
279.37
|
37.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
119,854.00
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
119,854.00
|
3,198.24
|
200.71
|
2,017.55
|
231.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
32.67
|
-60.69
|
11.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
3.77
|
61.92
|
2.58
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
--
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Jun-24
|
Jun-23
|
Sep-22
|
Jun-22
|
Sep-21
|
|---|---|---|---|---|---|
|
Meridian Bioscience (VIVO)
|
--
|
--
|
18.56
|
--
|
8.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|